Refine
Year of publication
- 2003 (1432) (remove)
Document Type
- Article (516)
- Doctoral Thesis (202)
- Part of Periodical (193)
- Working Paper (150)
- Review (89)
- Part of a Book (86)
- Preprint (45)
- Conference Proceeding (38)
- Book (36)
- Report (35)
Language
- German (918)
- English (449)
- French (36)
- Portuguese (17)
- Spanish (5)
- Multiple languages (4)
- Croatian (1)
- Italian (1)
- mis (1)
Keywords
- Deutschland (44)
- Bibliographie (38)
- Film (36)
- Deutsch (23)
- Frankfurt <Main> (20)
- Frankfurt <Main> / Universität (20)
- Rezension (18)
- Literatur (17)
- Vormärz (17)
- Hofmannsthal, Hugo von (15)
Institute
- Physik (93)
- Medizin (85)
- Rechtswissenschaft (74)
- Center for Financial Studies (CFS) (58)
- Extern (52)
- Wirtschaftswissenschaften (51)
- Biochemie und Chemie (48)
- Biowissenschaften (41)
- Gesellschaftswissenschaften (33)
- Pharmazie (22)
Die vorliegende Arbeit beschreibt die Herstellung von codierten Peptidbibliotheken durch kombinatorische Synthese, sowie deren Selektion auf Wechselwirkung mit einer verkürzten Sequenz der TAR-RNA des HI-Viruses.
Die zur Selektion benötigte RNA wurde dazu auf chemischem Wege hergestellt und mit einem Fluoreszensfarbstoff für eine optische Selektion markiert. Ausgehend von dieser RNA wurde ein Anfärbeassay entwickelt. Bei der Anwendung des Assays auf Tri- und Pentapeptide, die auf einem Polymerträger immobilisiert waren, zeigten sich einige intensiv leuchtende Polymerkügelchen. Die hellsten unter ihnen wurden selektiert. Die Synthese der Trimeren und Pentamerenbibliothek erfolgte zuvor an wasserquellbarem, polymerem Trägermaterial. Die Identifizierung der polymergebundenen Verbindungen erfolgte über die Codierung nach W.C. Still, welche im Rahmen dieser Dissertation in der Arbeitsgruppe von Hr. Prof. Göbel erfolgreich etabliert wurde und die einfache Unterscheidung zwischen Enantiomeren ermöglicht. Drei der am häufigsten auftretenden Trimerensequenzen wurden im Nachhinein erneut synthetisiert und Experimenten an Zellen zugeführt. Unabhängig davon, wurde ihre Wechselwirkung mit RNA als auch mit RNA-Peptid Komplexen direkt getestet.
Weiterhin wurde exemplarisch anhand von Aminopyridinen die Möglichkeit getestet, neuartige Synthesemonomere für die automatische Synthese polymergebundener Verbindungen darzustellen.
Die vorliegende Arbeit macht deutlich, dass man durch kombinatorische Synthese im Verbund mit gerichteter Selektion, die Entwicklung von in vitro RNA-Liganden für RNA mit bekannter Struktur vorantreiben kann. Umgekehrt müsste dies auch bald die Selektion von Liganden für strukturell nicht charakterisierte RNA ermöglichen.
Das nächste Ziel sollte, die Entwicklung weiterer Selektionstests sein und die Etablierung von NMR-Methoden, welche die genauen Bindungsmodi der selektierten Verbindungen an RNA aufklären, um somit die gezielte Synthese neuartiger Liganden vorantreiben zu können, da letztendlich das "Wie", für die Weiterentwicklung einer Leitstruktur ausschlaggebend ist.
Weiterhin sollten die Transportmechanismen von körperfremden Substanzen zu dem gewünschten Wirkort studiert werden, damit die vorab in vitro getestete Substanz auch im späteren Entwicklungsstadium in vivo die gewünschten Eigenschaften zeigen kann.
Die Transkription vieler Gene wird über den Acetylierungsgrad der Histone reguliert. Entsprechend erweiterte die Entdeckung von Histondeacetylase-Inhibitoren das Verständnis um Transkriptions-Repressoren und ihre Rolle in der Pathogenese beträchtlich. Zur Zeit stehen die Modifikationen der Histondeacetylasen (HDACs) sowie die biologischen Rollen der verschiedenen HDAC-Isoenzyme im Zentrum intensiver Forschungsarbeiten.
In der vorliegenden Arbeit wurde anhand verschiedener Zelllinien und mit murinem Primärmaterial nachgewiesen, dass das gut verträgliche Antiepileptikum Valproinsäure (VPA) ein potenter HDAC-Inhibitor ist. Dies zeigt sich daran, dass VPA in vivo die durch HDACs vermittelte transkriptionelle Repression aufhebt und zur Akkumulation hyperacetylierter Histone führt. In vitro Enzymassays weisen darauf hin, dass VPA selbst und nicht ein hypothetischer Metabolit die Histondeacetylasen hemmt. Darüber hinaus wurde mit Bindungs- und Kompetitionsstudien festgestellt, dass eine Interaktion von VPA mit dem katalytischen Zentrum der HDACs stattfindet.
Weitere Analysen zeigten, dass VPA bevorzugt Klasse I HDACs hemmt. Durch dieses Merkmal einer erhöhten Spezifität bei gleichzeitig guter Bioverfügbarkeit definiert VPA eine neue Klasse von HDAC-Inhibitoren. Hieraus ergeben sich Hinweise auf strukturelle Anforderungen, die ein HDAC-Inhibitor erfüllen muß, um spezifischer und weniger toxisch als konventionelle Chemotherapeutika zu wirken. Außerdem eröffnete das neu entdeckte pharmakologische Wirkungsspektrum von VPA auf HDACs Erkenntnisse um zusätzliche therapeutische Einsatzmöglichkeiten dieses etablierten Arzneimittels. Bereits jetzt wird VPA in klinischen Studien an Patienten mit Krebs verabreicht.
HDAC-Inhibitoren gelten als potentielle Medikamente für die Therapie maligner Neoplasien. Deshalb besteht großes Interesse an den molekularen Mechanismen, mit denen Substanzen dieser Wirkstoffklasse das Wachstum transformierter Zellen in vitro und in vivo hemmen. In den humanen Melanomzelllinien SK-Mel-37 und Mz-Mel-19 bewirken klinisch relevante VPA-Dosen eine zeit- und dosisabhängige Akkumulation von Zellzyklusinhibitoren und hyperacetylierten Histonen, morphologische Veränderungen und eine verringerte Proliferationsrate. Die verminderte Proliferation wird von einem veränderten Zellzyklusprofil und Apoptose unter Beteiligung sowohl der extrinsisch als auch der intrinsisch bedingten Caspase-Kaskade begleitet. Dies manifestiert sich in der Spaltung der Caspasen 3, 8 und 9, einer Schädigung der Mitochondrien, der apoptotischen PARP-Spaltung, einem Abbau der genomischen DNA und einer Inaktivierung des GFP-Proteins.
Diese Analysen in Melanomzellen sprechen dafür, dass die weitgehend selektive Wirkung von VPA auf Klasse I HDACs der Mechanismus ist, mit dem diese Substanz das Wachstum bestimmter Tumorzellen hemmt. Durch Genexpressions-Analysen konnten außerdem neue Modelle zum Einfluss von VPA auf solide Tumoren postuliert werden. Darüber hinaus wurde festgestellt, dass die Expression und Induzierbarkeit der Zellzyklusregulatoren p21WAF/CIP1 und p27Kip1 und des latent cytoplasmatischen Transkriptionsfaktors Stat1 Biomarker für die Sensitivität von Melanomzellen gegenüber HDAC-Inhibitoren sind. Im Einklang hiermit wird die proapoptotische Wirkung von VPA durch das Cytokin Interferon α und den S-Phase-Inhibitor Hydroxyharnstoff deutlich gesteigert. Diese Ergebnisse sprechen für den Einsatz von VPA in tierexperimentellen und klinischen Studien.
Aufgrund der Schlüsselrolle der HDACs für die physiologische und aberrante Genexpression ist es wichtig, die Mechanismen ihrer Regulation zu kennen. In der vorliegenden Arbeit wurde anhand zahlreicher kultivierter Zelllinien und mittels eines Mausmodells gezeigt, dass therapeutisch einsetzbare VPA-Dosen neben der Hemmung enzymatischer Aktivität auch zu einer isoenzymspezifischen Verringerung der Klasse I Histondeacetylase HDAC2 führen. Als Ursache hierfür konnten eine verstärkte Poly-Ubiquitinylierung und ein proteasomaler Abbau ermittelt werden. Gleichzeitig wurden die Beteiligung etlicher Proteasen und eine veränderte Synthese oder Prozessierung der HDAC2-mRNA als Mechanismen ausgeschlossen.
Expressionsanalysen identifizierten die E2 Ubiquitinkonjugase Ubc8 als von HDAC-Inhibitoren induziertes Gen. Mittels transienter Überexpression („Gain-of-Function“) und siRNA-Experimenten („Loss-of-Function“) konnte dieses Gen als limitierender Faktor des HDAC2-Umsatzes in vivo erkannt werden. Weiterhin wurde gezeigt, dass die E3 Ubiquitinligase RLIM spezifisch mit HDAC2 interagiert. Die Expression von RLIM beziehungsweise seine enzymatische Funktion beeinflusst die HDAC2-Konzentration in vivo. Hierbei kann VPA klar von dem HDACInhibitor Trichostatin A (TSA) abgegrenzt werden. Dieser hemmt ein breites Spektrum an HDACs und induziert Ubc8, führt aber gleichzeitig zu einem proteasomal vermittelten Abbau des RLIM-Proteins. Analysen mit überexprimiertem RLIM zeigten, dass TSA aufgrund dieses Mechanismus nicht in der Lage ist, den Abbau von HDAC2 zu induzieren. Somit ist im Rahmen dieser Arbeit die Ubiquitinylierungs-Maschinerie für HDAC2 charakterisiert worden. Hierdurch sind neue Aspekte zum Zusammenspiel zwischen dem Ubiquitin-Proteasom-System und der Transkriptionsrepression nachgewiesen worden.
Isoenzymspezifische HDAC-Inhibitoren können zur Aufklärung der Funktion einzelner Histondeacetylasen beitragen, insbesondere wenn Knock-Out-Studien zu aufwendig oder aufgrund embryonaler Letalität nicht durchführbar sind. Die Wichtigkeit dieser Analysen wird gerade bei HDAC2 deutlich, da diese Histondeacetylase in vielen soliden und hämatologischen Tumoren überexprimiert ist, und ihre Deregulation möglicherweise zur Krebsentstehung beiträgt. Die in der vorliegenden Arbeit identifizierte Regulation dieses HDAC-Isoenzyms könnte Hinweise auf den Ablauf eines malignen Transformationsprozesses geben. Darüber hinaus zeigt der nachgewiesene Regulationsmechanismus Erfordernisse und potentielle Zielstrukturen einer pharmakologischen Intervention auf. Schließlich könnten die Selektivität von VPA für Klasse I HDACs zusammen mit der Spezifität für HDAC2 die Gründe für die geringen Nebenwirkungen der VPA-Behandlung bei gleichzeitigem Auftreten antitumoraler Effekte sein.
Die Endothelzellmigration ist ein wesentlicher Prozess für die Angiogenese, Neovaskularisierung und Reendothelialisierung. Im ersten Teil der Arbeit wurde der Effekt von Schubspannung auf die Endothelzellmigration, die Beteiligung der Integrine und der Integrin-abhängigen Signaltransduktionswege mittels "scratched wound assay" untersucht. Die Schubspannungs-induzierte Endothelzellmigration war signifikant durch Integrin-blockierende RGD-Peptide oder neutralisierende Antikörper gegen die Integrin-Untereinheiten α5β1 reduziert, wohingegen Antikörper gegen αvβ3 oder α2β1 keinen Effekt hatten. Die Integrin-Expression von α5 und β1 war besonders in der migrierenden Zellfront der Wunde erhöht. Passend zu der wichtigen Rolle der Integrine in der Schubspannungs-induzierten Endothelzellmigration hemmte eine Blockade des Integrin-assoziierten Adapterproteins Shc durch eine dominant negative Mutante die Schubspannungs-induzierte Zellmigration. Zusätzlich konnte gezeigt werden, dass die pharmakologische Hemmung der MAP Kinase ERK1/2 oder der PI3K die Schubspannungs-induzierte Endothelzellmigration verhinderte. Im Gegensatz dazu hatte die Hemmung der NO-Synthase keinen Effekt.
Im zweiten Teil der Arbeit wurde die VEGF-vermittelte Endothelzellmigration untersucht. Im Gegensatz zu den Befunden, dass laminare Schubspannung NO-unabhängig die Endothelzellmigration stimuliert, konnte die VEGF-vermittelte Endothelzellmigration durch NOS-Inhibitoren blockiert werden. Des weiteren wurde die Beteiligung der Akt-mediierten eNOS Phosphorylierung in der VEGF- induzierten Endothelzellmigration ebenfalls mittels "scratched wound assay" untersucht, da bekannt ist, dass Akt die eNOS über eine Phosphorylierung an Serin 1177 aktivieren kann. Die Überexpression einer dominant-negativen Akt-Mutante verhindert die VEGF-induzierte Zellmigration. Im Gegensatz dazu stimulierte die Überexpression einer konstitutiv-aktiven Akt-Mutante die Endothelzellmigration, auch in Abwesenheit von VEGF. Die Überexpression eines phosphomimetischen eNOS-Konstruktes (S1177D) führte ebenfalls zu einer verstärkten Zellmigration, wohingegen die nicht mehr phosphorylierbare und somit nicht mehr aktivierbare eNOS-Mutante (S1177A) die VEGF-induzierte Endothelzellmigration komplett hemmte.
Zusammengefasst zeigen diese Daten, dass die VEGF- und Schubspannungsinduzierte Endothelzellmigration wesentlich zu der beschleunigten Reendothelialisierung von verletztem Endothel beiträgt, wie es beispielsweise nach einer Ballondilatation der Fall ist. Es konnte gezeigt werden, dass laminarer Blutfluss über die Integrine α5β1 NO-unabhängig die Migration mediiert und dass der Wachstumsfaktor VEGF über die Protein Kinase Akt NO-abhängig die Endothelzellmigration stimuliert.
Biglycan, a nitric oxide-regulated gene, affects adhesion, growth, and survival of mesangial cells
(2003)
During glomerular inflammation mesangial cells are the major source and target of nitric oxide that pro-foundly influences proliferation, adhesion, and death of mesangial cells. The effect of nitric oxide on the mRNA expression pattern of cultured rat mesangial cells was therefore investigated by RNA-arbitrarily-primed polymerase chain reaction. Employing this approach, biglycan expression turned out to be down-regulated time- and dose-dependently either by interleukin-1beta-stimulated endogenous nitric oxide production or by direct application of the exogenous nitric oxide donor, diethylenetriamine nitric oxide. There was a corresponding decline in the rate of biglycan biosynthesis and in the steady state level of this proteoglycan. In vivo, in a model of mesangioproliferative glomerulonephritis up-regulation of inducible nitric-oxide synthase mRNA was associated with reduced expression of biglycan in isolated glomeruli. Biglycan expression could be normalized, both in vitro and in vivo, by using a specific inhibitor of the inducible nitric-oxide synthase, l-N6-(l-iminoethyl)-l-lysine dihydrochloride. Further studies showed that biglycan inhibited cell adhesion on type I collagen and fibronectin because of its binding to these substrates. More importantly, biglycan protected mesangial cells from apoptosis by decreasing caspase-3 activity, and it counteracted the proliferative effects of platelet-derived growth factor-BB. These findings indicate a signaling role of biglycan and describe a novel pathomechanism by which nitric oxide modulates the course of renal glomerular disease through regulation of biglycan expression.
Membrane-bound complex I (NADH:ubiquinone oxidoreductase) of the respiratory chain is considered the main site of mitochondrial radical formation and plays a major role in many mitochondrial pathologies. Structural information is scarce for complex I, and its molecular mechanism is not known. Recently, the 49-kDa subunit has been identified as part of the "catalytic core" conferring ubiquinone reduction by complex I. We found that the position of the 49-kDa subunit is clearly separated from the membrane part of complex I, suggesting an indirect mechanism of proton translocation. This contradicts all hypothetical mechanisms discussed in the field that link proton translocation directly to redox events and suggests an indirect mechanism of proton pumping by redox-driven conformational energy transfer.
Cardiolipin stabilized supercomplexes of Saccharomyces cerevisiae respiratory chain complexes III and IV (ubiquinol:cytochrome c oxidoreductase and cytochrome c oxidase, respectively), but was not essential for their formation in the inner mitochondrial membrane because they were found also in a cardiolipin-deficient strain. Reconstitution with cardiolipin largely restored wild-type stability. The putative interface of complexes III and IV comprises transmembrane helices of cytochromes b and c1 and tightly bound cardiolipin. Subunits Rip1p, Qcr6p, Qcr9p, Qcr10p, Cox8p, Cox12p, and Cox13p and cytochrome c were not essential for the assembly of supercomplexes; and in the absence of Qcr6p, the formation of supercomplexes was even promoted. An additional marked effect of cardiolipin concerns cytochrome c oxidase. We show that a cardiolipin-deficient strain harbored almost inactive resting cytochrome c oxidase in the membrane. Transition to the fully active pulsed state occurred on a minute time scale.
The renin-angiotensin-aldosterone system plays a pivotal role in the regulation of salt and water homeostasis. Here, we demonstrate the expression and functional role of cGMP-dependent protein kinases (PKGs) in rat adrenal cortex. Expression of PKG II is restricted to adrenal zona glomerulosa (ZG) cells, whereas PKG I is localized to the adrenal capsule and blood vessels. Activation of the aldosterone system by a low sodium diet up-regulated the expression of PKG II, however, it did not change PKG I expression in adrenal cortex. Both, activation of PKG II in isolated ZG cell and adenoviral gene transfer of wild type PKG II into ZG cells enhanced aldosterone production. In contrast, inhibition of PKG II as well as infection with a PKG II catalytically inactive mutant had an inhibitory effect on aldosterone production. Steroidogenic acute regulatory (StAR) protein that regulates the rate-limiting step in steroidogenesis is a new substrate for PKG II and can be phosphorylated by PKG II in vitro at serine 55/56 and serine 99. Stimulation of aldosterone production by PKG II in contrast to stimulation by PKA did not activate StAR gene expression in ZG cells. The results presented indicate that PKG II activity in ZG cells is important for maintaining basal aldosterone production.
Atrial natriuretic peptide (ANP) plays a key regulatory role in arterial blood pressure homeostasis. We recently generated mice with selective deletion of the ANP receptor, guanylyl cyclase-A (GC-A), in vascular smooth muscle (SMC GC-A knockout (KO) mice) and reported that resting arterial blood pressure was completely normal in spite of clear abolition of the direct vasodilating effects of ANP (Holtwick, R., Gotthardt, M., Skryabin, B., Steinmetz, M., Potthast, R., Zetsche, B., Hammer, R. E., Herz, J., and Kuhn M. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 7142–7147). The purpose of this study was to clarify mechanisms compensating for the missing vasodilator responses to ANP. In particular, we analyzed the effect of the endothelial, cGMP-mediated vasodilators C-type natriuretic peptide and nitric oxide (NO). In isolated arteries from SMC GC-A KO mice, the vasorelaxing sensitivity to sodium nitroprusside and the endothelium-dependent vasodilator, acetylcholine, was significantly greater than in control mice. There was no difference in responses to C-type natriuretic peptide or to the activator of cGMP-dependent protein kinase I, 8-para-chlorophenylthio-cGMP. The aortic expression of soluble GC (sGC), but not of endothelial NO synthase or cGMP-dependent protein kinase I, was significantly increased in SMC GC-A KO mice. Chronic oral treatment with the NO synthase inhibitor Nw-nitro-l-arginine methyl ester increased arterial blood pressure, the effect being significantly enhanced in SMC GC-A KO mice. We conclude that SMC GC-A KO mice exhibit a higher vasodilating sensitivity to NO. This can be attributed to an enhanced expression of sGC, whereas the expression and/or activity levels of downstream cGMP-effector pathways are not involved. Increased vasodilating responsiveness to endothelial NO contributes to compensate for the missing vasodilating effect of ANP in SMC GC-A KO mice.
Atovaquone is a substituted 2-hydroxynaphthoquinone that is used therapeutically to treat Plasmodium falciparum malaria, Pneumocystis carinii pneumonia, and Toxoplasma gondii toxoplasmosis. It is thought to act on these organisms by inhibiting the cytochrome bc1 complex. We have examined the interaction of atovaquone with the bc1 complex isolated from Saccharomyces cerevisiae, a surrogate, nonpathogenic fungus. Atovaquone inhibits the bc1 complex competitively with apparent Ki = 9 nm, raises the midpoint potential of the Rieske iron-sulfur protein from 285 to 385 mV, and shifts the g values in the EPR spectrum of the Rieske center. These results indicate that atovaquone binds to the ubiquinol oxidation pocket of the bc1 complex, where it interacts with the Rieske iron-sulfur protein. A computed energy-minimized structure for atovaquone liganded to the yeast bc1 complex suggests that a phenylalanine at position 275 of cytochrome b in the bovine bc1 complex, as opposed to leucine at the equivalent position in the yeast enzyme, is responsible for the decreased sensitivity of the bovine bc1 complex (Ki = 80 nm) to atovaquone. When a L275F mutation was introduced into the yeast cytochrome b, the sensitivity of the yeast enzyme to atovaquone decreased (Ki = 100 nm) with no loss in activity, confirming that the L275F exchange contributes to the differential sensitivity of these two species to atovaquone. These results provide the first molecular description of how atovaquone binds to the bc1 complex and explain the differential inhibition of the fungal versus mammalian enzymes.
Pin1 is a peptidyl-prolyl cis/trans isomerase (PPIase) essential for cell cycle regulation. Pin1-catalyzed peptidyl-prolyl isomerization provides a key conformational switch to activate phosphorylation sites with the common phospho-Ser/Thr-Pro sequence motif. This motif is ubiquitously exploited in cellular response to a variety of signals. Pin1 is able to bind phospho-Ser/Thr-Pro-containing sequences at two different sites that compete for the same substrate. One binding site is located within the N-terminal WW domain, which is essential for protein targeting and localization. The other binding site is located in the C-terminal catalytic domain, which is structural homologous to the FK506-binding protein (FKBP) class of PPIases. A flexible linker of 12 residues connects the WW and catalytic domain. To characterize the structure and dynamics of full-length Pin1 in solution, high resolution NMR methods have been used to map the nature of interactions between the two domains of Pin1. In addition, the influence of target peptides on domain interactions has been investigated. The studies reveal a dynamic picture of the domain interactions. 15N spin relaxation data, differential chemical shift mapping, and residual dipolar coupling data indicate that Pin1 can either behave as two independent domains connected by the flexible linker or as a single intact domain with some amount of hinge bending motion depending on the sequence of the bound peptide. The functional importance of the modulation of relative domain flexibility in light of the multitude of interaction partners of Pin1 is discussed.
Recently, we reported that in crude enzyme preparations, a monocyte-derived soluble protein (M-DSP) renders 5-lipoxygenase (5-LO) activity Ca2+-dependent. Here we provide evidence that this M-DSP is glutathione peroxidase (GPx)-1. Thus, the inhibitory effect of the M-DSP on 5-LO could be overcome by the GPx-1 inhibitor mercaptosuccinate and by the broad spectrum GPx inhibitor iodoacetate, as well as by addition of 13(S)-hydroperoxy-9Z,11E-octadecadienoic acid (13(S)-HPODE). Also, the chromatographic characteristics and the estimated molecular mass (80-100 kDa) of the M-DSP fit to GPx-1 (87 kDa), and GPx-1, isolated from bovine erythrocytes, mimicked the effects of the M-DSP. Intriguingly, only a trace amount of thiol (10 micro M GSH) was required for reduction of 5-LO activity by GPx-1 or the M-DSP. Moreover, the requirement of Ca2+ allowing 5-LO product synthesis in various leukocytes correlated with the respective GPx-1 activities. Mutation of the Ca2+ binding sites within the C2-like domain of 5-LO resulted in strong reduction of 5-LO activity by M-DSP and GPx-1, also in the presence of Ca2+. In summary, our data suggest that interaction of Ca2+ at the C2-like domain of 5-LO protects the enzyme against the effect of GPx-1. Apparently, in the presence of Ca2+, a low lipid hydroperoxide level is sufficient for 5-LO activation.
Nisin-producing Lactococcus lactis strains show a high degree of resistance to the action of nisin, which is based upon expression of the self-protection (immunity) genes nisI, nisF, nisE, and nisG. Different combinations of nisin immunity genes were integrated into the chromosome of a nisin-sensitive Bacillus subtilis host strain under the control of an inducible promoter. For the recipient strain, the highest level of acquired nisin tolerance was achieved after coordinated expression of all four nisin immunity genes. But either the lipoprotein NisI or the ABC transporter-homologous system NisFEG, respectively, were also able to protect the Bacillus host cells. The acquired immunity was specific to nisin and provided no tolerance to subtilin, a closely related lantibiotic. Quantitative in vivo peptide release assays demonstrated that NisFEG diminished the quantity of cell-associated nisin, providing evidence that one role of NisFEG is to transport nisin from the membrane into the extracellular space. NisI solubilized from B. subtilis membrane vesicles and recombinant hexahistidine-tagged NisI from Escherichia coli interacted specifically with nisin and not with subtilin. This suggests a function of NisI as a nisin-intercepting protein.
Na,K-ATPase mediates net electrogenic transport by extruding three Na+ ions and importing two K+ ions across the plasma membrane during each reaction cycle. We mutated putative cation coordinating amino acids in transmembrane hairpin M5-M6 of rat Na,K-ATPase: Asp776 (Gln, Asp, Ala), Glu779 (Asp, Gln, Ala), Asp804 (Glu, Asn, Ala), and Asp808 (Glu, Asn, Ala). Electrogenic cation transport properties of these 12 mutants were analyzed in two-electrode voltage-clamp experiments on Xenopus laevis oocytes by measuring the voltage dependence of K+-stimulated stationary currents and pre-steady-state currents under electrogenic Na+/Na+ exchange conditions. Whereas mutants D804N, D804A, and D808A hardly showed any Na+/K+ pump currents, the other constructs could be classified according to the [K+] and voltage dependence of their stationary currents; mutants N776A and E779Q behaved similarly to the wild-type enzyme. Mutants E779D, E779A, D808E, and D808N had in common a decreased apparent affinity for extracellular K+. Mutants N776Q, N776D, and D804E showed large deviations from the wild-type behavior; the currents generated by mutant N776D showed weaker voltage dependence, and the current-voltage curves of mutants N776Q and D804E exhibited a negative slope. The apparent rate constants determined from transient Na+/Na+ exchange currents are rather voltage-independent and at potentials above -60 mV faster than the wild type. Thus, the characteristic voltage-dependent increase of the rate constants at hyperpolarizing potentials is almost absent in these mutants. Accordingly, dislocating the carboxamide or carboxyl group of Asn776 and Asp804, respectively, decreases the extracellular Na+ affinity.
We report the first evidence for the formation of the "607- and 580-nm forms" in the cytochrome oxidase aa3/H2O2 reaction without the involvement of tyrosine 280. The pKa of the 607-580-nm transition is 7.5. The 607-nm form is also formed in the mixed valence cytochrome oxidase/O2 reaction in the absence of tyrosine 280. Steady-state resonance Raman characterization of the reaction products of both the wild-type and Y280H cytochrome aa3 from Paracoccus denitrificans indicate the formation of six-coordinate low spin species, and do not support, in contrast to previous reports, the formation of a porphyrin pi-cation radical. We observe three oxygen isotope-sensitive Raman bands in the oxidized wild-type aa3/H2O2 reaction at 804, 790, and 358 cm-1. The former two are assigned to the Fe(IV)[double bond]O stretching mode of the 607- and 580-nm forms, respectively. The 14 cm-1 frequency difference between the oxoferryl species is attributed to variations in the basicity of the proximal to heme a3 His-411, induced by the oxoferryl conformations of the heme a3-CuB pocket during the 607-580-nm transition. We suggest that the 804-790 cm-1 oxoferryl transition triggers distal conformational changes that are subsequently communicated to the proximal His-411 heme a3 site. The 358 cm-1 mode has been found for the first time to accumulate with the 804 cm-1 mode in the peroxide reaction. These results indicate that the mechanism of oxygen reduction must be reexamined.
Cholecystokinin (CCK) and related peptides are potent growth factors in the gastrointestinal tract and may be important for human cancer. CCK exerts its growth modulatory effects through G(q)-coupled receptors (CCK(A) and CCK(B)) and activation of extracellular signal-regulated protein kinase 1/2 (ERK1/2). In the present study, we investigated the different mechanisms participating in CCK-induced activation of ERK1/2 in pancreatic AR42J cells expressing both CCK(A) and CCK(B). CCK activated ERK1/2 and Raf-1 to a similar extent as epidermal growth factor (EGF). Inhibition of EGF receptor (EGFR) tyrosine kinase or expression of dominant-negative Ras reduced CCK-induced ERK1/2 activation, indicating participation of the EGFR and Ras in CCK-induced ERK1/2 activation. However, compared with EGF, CCK caused only small increases in tyrosine phosphorylation of the EGFR and Shc, Shc-Grb2 complex formation, and Ras activation. Signal amplification between Ras and Raf in a CCK-induced ERK cascade appears to be mediated by activation of protein kinase Cepsilon (PKCepsilon), because 1) down-modulation of phorbol ester-sensitive PKCs inhibited CCK-induced activation of Ras, Raf, and ERK1/2 without influencing Shc-Grb2 complex formation; 2) PKCepsilon, but not PKCalpha or PKCdelta, was detectable in Raf-1 immunoprecipitates, although CCK activated all three PKC isoenzymes. In addition, the present study provides evidence that the Src family tyrosine kinase Yes is activated by CCK and mediates CCK-induced tyrosine phosphorylation of Shc. Furthermore, we show that CCK-induced activation of the EGFR and Yes is achieved through the CCK(B) receptor. Together, our data show that different signals emanating from the CCK receptors mediate ERK1/2 activation; activation of Yes and the EGFR mediate Shc-Grb2 recruitment, and activation of PKC, most likely PKCepsilon, augments CCK-stimulated ERK1/2 activation at the Ras/Raf level.
Physiological conditions which lead to changes in total carotenoid content in tomato plantlets were identified. Carotenoid levels were found to increase after the onset of a dark period during a normal 24h cycle. This rapid initial increase is followed by a steady decrease in carotenoid content throughout the night. A decrease in the expression of several carotenogenic genes, namely pds, zds (carotenoid desaturases) and ptox (plastid terminal oxidase), was observed following the removal of the light (when carotenoid content is at its highest). An increase in gene expression was observed before the return to light for pds and zds (when carotenoid levels were at their lowest), or following the return to light for ptox. The phytoene desaturation inhibitor norflurazon leads to a decrease coloured carotenoid content and, in the light, this correlated with pds and zds gene induction. In the dark, norflurazon treatment led to only a weak decrease in carotenoid content and only a small increase in pds and zds gene expression. The striking absence of phytoene accumulation under norflurazon treatment in the dark suggests a down-regulation of carotenoid formation in darkness. However, prolonged dark conditions, or treatment with photosynthetic inhibitors, surprisingly led to higher carotenoid levels, which correlated with decreased expression of most examined genes. In addition to light, which acts in a complex way on carotenoid accumulation and gene expression, our results are best explained by a regulatory effect of carotenoid levels on the expression of several biosynthetic genes. In addition, monitoring of protein amounts for phytoene desaturase and plastid terminal oxidase (which sometimes do not correlate with gene expression) indicate an even more complex regulatory pattern.
Receptor tyrosine kinases of the epidermal growth factor (EGF) receptor family regulate essential cellular functions such as proliferation, survival, migration, and differentiation but also play central roles in the etiology and progression of tumors. We have identified short peptide sequences from a random peptide library integrated into the thioredoxin scaffold protein, which specifically bind to the intracellular domain of the EGF receptor (EGFR). These molecules have the potential to selectively inhibit specific aspects of EGF receptor signaling and might become valuable as anticancer agents. Intracellular expression of the aptamer encoding gene construct KDI1 or introduction of bacterially expressed KDI1 via a protein transduction domain into EGFR-expressing cells results in KDI1·EGF receptor complex formation, a slower proliferation, and reduced soft agar colony formation. Aptamer KDI1 did not summarily block the EGF receptor tyrosine kinase activity but selectively interfered with the EGF-induced phosphorylation of the tyrosine residues 845, 1068, and 1148 as well as the phosphorylation of tyrosine 317 of p46 Shc. EGF-induced phosphorylation of Stat3 at tyrosine 705 and Stat3-dependent transactivation were also impaired. Transduction of a short synthetic peptide aptamer sequence not embedded into the scaffold protein resulted in the same impairment of EGF-induced Stat3 activation.
There is evidence that endothelial nitric-oxide synthase (eNOS) is regulated by reciprocal dephosphorylation of Thr497 and phosphorylation of Ser1179. To examine the interrelationship between these sites, cells were transfected with wild-type (WT), T497A, T497D, S1179D, and T497A/S1179D eNOS and activity, NO release and eNOS localization were assessed. Although eNOS T497A, S1179D and T497A/S1179D eNOS had greater enzymatic activity than did WT eNOS in lysates, basal production of NO from cells was markedly reduced in cells transfected with T497A and T497A/S1179D eNOS but augmented in cells transfected with S1179D eNOS. Stimulating cells with ATP or ionophore normalized the loss of function seen with T497A and T497A/S1179D eNOS to levels observed with WT and S1179D eNOS, respectively. Despite these functional differences, the localization of eNOS mutants were similar to WT. Because both T497A and T497A/S1179D eNOS exhibited higher enzyme activity but reduced production of NO, we examined whether these mutations were “uncoupling” NO synthesis. T497A and T497A/S1179D eNOS generated 2-3 times more superoxide anion than WT eNOS, and both basal and stimulated interactions of T497A/S1179D eNOS with hsp90 were reduced in co-immunoprecipitation experiments. Thus, the phosphorylation/dephosphorylation of Thr497 may be an intrinsic switch mechanism that determines whether eNOS generates NO versus superoxide in cells.
Cytochrome P450-derived epoxyeicosatrienoic acids (EETs) stimulate endothelial cell proliferation and angiogenesis. In this study, we investigated the involvement of the forkhead box, class O (FOXO) family of transcription factors and their downstream target p27Kip1 in EET-induced endothelial cell proliferation. Incubation of human umbilical vein endothelial cells with 11,12-EET induced a time- and dose-dependent decrease in p27Kip1 protein expression, whereas p21Cip1 was not significantly affected. This effect on p27Kip1 protein was associated with decreased mRNA levels as well as p27Kip1 promoter activity. 11,12-EET also stimulated the time-dependent phosphorylation of Akt and of the forkhead factors FOXO1 and FOXO3a, effects prevented by the phosphatidylinositol 3-kinase inhibitor LY 294002. Transfection of endothelial cells with either a dominant-negative or an “Akt-resistant”/constitutively active FOXO3a mutant reversed the 11,12-EET-induced down-regulation of p27Kip1, whereas transfection of a constitutive active Akt decreased p27Kip1 expression independently of the presence or absence of 11,12-EET. To determine whether these effects are involved in EET-induced proliferation, endothelial cells were transfected with the 11,12-EET-generating epoxygenase CYP2C9. Transfection of CYP2C9 elicited endothelial cell proliferation and this effect was inhibited in cells co-transfected with CYP2C9 and either a dominant-negative Akt or constitutively active FOXO3a. Reducing FOXO expression using RNA interference, on the other hand, attenuated p27Kip1 expression and stimulated endothelial cell proliferation. These results indicate that EET-induced endothelial cell proliferation is associated with the phosphatidylinositol 3-kinase/Akt-dependent phosphorylation and inactivation of FOXO factors and the subsequent decrease in expression of the cyclin-dependent kinase inhibitor p27Kip1.